Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

FranceBack to France

Clinical trials in Lille – page 95

1 340 clinical trials in Lille, France across 3 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

FranceOur site in FranceEssaisCliniques.fr(opens in a new tab)
Lille at a glance
1 340
clinical trials
  • Research sites3
Type of trial
Recruitment status
Quick filters

1 340 trials in Lille

Open in trial search

Primary biliary cholangitis

Not recruiting

Study on the Effects of Obeticholic Acid and Bezafibrate for Patients with Primary Biliary Cholangitis Who Cannot Tolerate Ursodeoxycholic Acid

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Bezafibrate
  • Sponsor:Intercept Pharmaceuticals Inc.

Chronic inflammatory demyelinating polyradiculoneuropathy

Not recruiting

Study on the Effects and Safety of Riliprubart for Patients with Chronic Inflammatory Demyelinating Polyneuropathy Unresponsive to Usual Treatments

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Riliprubart
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Pulmonary arterial hypertension

Not recruiting

Study on Long-term Safety of Seralutinib for Patients with Pulmonary Arterial Hypertension

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Seralutinib
  • Sponsor:GB002 Inc.

Factor VIII deficiency

Not recruiting

Long-Term Safety Study of Valoctocogene Roxaparvovec for Patients with Severe Hemophilia A

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Valoctocogene Roxaparvovec
  • Sponsor:Biomarin Pharmaceutical Inc.

Asthma

Not recruiting

Study Comparing Depemokimab, Mepolizumab, and Benralizumab for Adults and Adolescents with Severe Eosinophilic Asthma

Registered drug
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Benralizumab
  • Sponsor:Glaxosmithkline Research & Development Limited

Chronic myeloid leukaemia

Not recruiting

Study on the Tolerability and Efficacy of Asciminib vs. Nilotinib for Adults with Newly Diagnosed Philadelphia Chromosome Positive Chronic Myeloid Leukemia

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Nilotinib
  • Sponsor:Novartis Pharma AG

Crohn's disease

Not recruiting

Study on the Effectiveness and Safety of Risankizumab for Patients with Moderate to Severe Crohn's Disease

Investigational
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Risankizumab
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Primary amyloidosis

Not recruiting

Study on Daratumumab, Cyclophosphamide, Bortezomib, and Dexamethasone for Patients with Newly Diagnosed Systemic AL Amyloidosis

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Bortezomib
  • Sponsor:Janssen Cilag International

Non-small cell lung cancer+4

Not recruiting

Study on the Effectiveness and Safety of Osimertinib for Patients with Stage IB-IIIA Non-Small Cell Lung Cancer After Tumor Removal

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Osimertinib
  • Sponsor:AstraZeneca AB

Parkinson's disease

Not recruiting

Study on the Long-Term Safety of ND0612 (Carbidopa, Levodopa) Infusion for Patients with Advanced Parkinson's Disease

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Carbidopa
  • Sponsor:Neuroderm Ltd.

Study on Melanoma Treatment: Comparing Encorafenib and Binimetinib with Ipilimumab and Nivolumab for Patients with BRAF V600 Mutation

Not recruiting
Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Binimetinib
  • Sponsor:European Organisation For Research And Treatment Of Cancer

Cystic fibrosis

Not recruiting

Study on Long-term Safety of VX-121, Tezacaftor, and Deutivacaftor in Patients with Cystic Fibrosis

Registered drugNo placebo
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Deutivacaftor
  • Sponsor:Vertex Pharmaceuticals Inc.

Other cities in France

The busiest research cities in the country

All 382 cities in France

Clinical research in Lille

What the registry says about research in the country

01 Oncology Research

Groundbreaking studies focusing on head and neck squamous cell carcinoma, exploring novel treatment combinations and targeted therapies. Additional research includes investigations into pancreatic cancer and gastric cancer treatments.

  • Advanced cancer therapies
  • Targeted molecular treatments
  • Combination therapy approaches

Studies are evaluating innovative therapeutic agents and their effectiveness in treating various forms of cancer.

02 Neurological Disorders

Comprehensive research into Alzheimer's disease and Amyotrophic Lateral Sclerosis, examining new treatment approaches and disease mechanisms. Studies also include investigations of essential tremor treatments.

  • Neurodegenerative diseases
  • Movement disorders
  • Brain imaging studies

Research focuses on understanding disease progression and developing targeted interventions.

03 Autoimmune and Inflammatory Conditions

Innovative trials examining treatments for Crohn's disease and Multiple Sclerosis. Research includes novel approaches to managing chronic inflammatory conditions and immune system disorders.

  • Inflammatory bowel diseases
  • Immunotherapy approaches
  • Disease modification strategies

Studies aim to improve treatment outcomes and develop more effective therapeutic options.

Back to FranceAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.